RBM45 Inhibitors
Chemical inhibitors of RBM45 include a range of molecules that target different cellular pathways, which can indirectly lead to the inhibition of this protein's function. Alsterpaullone and Roscovitine, both cyclin-dependent kinase inhibitors, work by disrupting the cell cycle regulation, a critical process where RBM45 is known to participate. By halting the cell cycle, these inhibitors can prevent RBM45 from carrying out its role in cell cycle checkpoints. Similarly, LY294002 and Wortmannin, which are phosphoinositide 3-kinase (PI3K) inhibitors, can interrupt signaling pathways that are essential for a variety of cellular functions, including RNA processing in which RBM45 is implicated. The disruption of PI3K signaling can lead to a functional inhibition of RBM45 by affecting its associated RNA processing activities.
Further down the signaling cascade, U0126 and SB203580 inhibit the MAPK/ERK and p38 MAPK pathways, respectively. By blocking these kinases, the inhibitors can affect the stress response mechanisms and RNA processing events within the cell, where RBM45 plays a vital role. Rapamycin's inhibition of the mTOR pathway can interfere with RBM45's involvement in regulating protein synthesis and RNA binding, as mTOR is a central regulator of cell growth and protein synthesis. Cycloheximide, which inhibits the translocation step in protein synthesis, can lead to a decreased formation of protein-RNA complexes that RBM45 is a part of, thereby inhibiting its function. Thapsigargin and Brefeldin A disrupt cellular homeostasis by targeting calcium signaling and protein transport, respectively, both of which are crucial for the proper functioning of RBM45 in RNA-protein complexes. MG132's proteasome inhibition can lead to an accumulation of aberrant proteins that can indirectly interfere with RBM45's role in RNA processing. Lastly, Actinomycin D binds to DNA and inhibits RNA polymerase activity, which can reduce the transcription of RNAs that interact with RBM45, thereby indirectly inhibiting RBM45's involvement in RNA metabolism and processing.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases (CDKs) which are involved in cell cycle regulation. RBM45 has been shown to be associated with cell cycle progression, and inhibition of CDKs would disrupt the cell cycle, thereby functionally inhibiting RBM45 activity linked to cell cycle checkpoints. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is another CDK inhibitor that could impact RBM45 by hindering the phosphorylation state of proteins involved in the cell cycle, thereby indirectly inhibiting the functional activity of RBM45 associated with the cell cycle. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor; PI3K signaling is implicated in a broad range of cellular functions, including those related to RNA processing in which RBM45 is involved. Inhibition of PI3K could therefore disrupt processes that are crucial for RBM45's functional roles. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, another PI3K inhibitor, could similarly interfere with the PI3K pathway, potentially inhibiting the cellular functions and processes that RBM45 is known to be involved in, such as RNA processing and transport. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, key kinases in the MAPK/ERK pathway. Since RBM45 is known to play a role in RNA metabolism, and the MAPK/ERK pathway is involved in various cellular functions, inhibition of MEK1/2 could disrupt functions of RBM45 in RNA processing. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor; the p38 MAPK pathway is involved in stress responses and RNA processing, and by inhibiting this pathway, SB203580 could indirectly inhibit the functional activity of RBM45 related to these processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is part of signaling pathways that regulate protein synthesis and cell growth. As RBM45 is associated with RNA binding and regulation, inhibition of mTOR could disrupt these RBM45-linked processes. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by interfering with the translocation step in protein synthesis on ribosomes. This general inhibition could lead to a decrease in RBM45 function since protein-RNA complexes that include RBM45 would not be effectively formed. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin disrupts calcium homeostasis by inhibiting the Sarco/Endoplasmic Reticulum Ca2+-ATPase (SERCA). Since calcium signaling can influence many aspects of cell function, including those associated with RBM45's role, this could indirectly inhibit RBM45. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts protein transport by inhibiting the exchange of protein ADP-ribosylation factor. Protein transport is essential for proper RNA-protein complex function, which could indirectly inhibit the functional role of RBM45 in these complexes. | ||||||